Top Page
Radiopharm Theranostics Limited
(Sydney:RAD)
Radiopharm Theranostics Limited (RAD) vs. iShares MSCI Australia ETF (EWA)
Radiopharm Theranostics Limited Business Overview & Revenue Model
Radiopharm Theranostics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.40M | 13.40M | 299.23K | 292.36K | 8.83K | 0.00 |
| Gross Profit | 9.81M | 9.81M | -21.31M | -3.00M | -2.97M | 0.00 |
| EBITDA | -31.65M | -31.65M | -45.38M | -37.11M | -18.04M | -484.75K |
| Net Income | -36.70M | -36.70M | -47.95M | -34.61M | -30.34M | -485.19K |
Balance Sheet | ||||||
| Total Assets | 86.48M | 86.48M | 72.04M | 74.95M | 83.38M | 33.44K |
| Cash, Cash Equivalents and Short-Term Investments | 29.12M | 29.12M | 18.58M | 11.70M | 26.98M | 27.09K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.00K |
| Total Liabilities | 43.61M | 43.61M | 44.68M | 29.37M | 20.42M | 158.14K |
| Stockholders Equity | 44.79M | 44.79M | 28.12M | 44.38M | 62.96M | -124.70K |
Cash Flow | ||||||
| Free Cash Flow | -36.65M | -36.65M | -22.98M | -24.73M | -38.25M | -32.91K |
| Operating Cash Flow | -36.65M | -36.65M | -22.98M | -23.20M | -9.91M | -32.91K |
| Investing Cash Flow | 1.77M | 1.77M | 0.00 | -1.53M | -28.37M | 0.00 |
| Financing Cash Flow | 45.43M | 45.43M | 29.88M | 9.22M | 65.11M | 60.00K |
Radiopharm Theranostics Limited Technical Analysis
Radiopharm Theranostics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$85.06M | -1.35 | -100.67% | ― | 1114.27% | 85.66% | |
55 Neutral | AU$126.24M | -12.09 | -71.87% | ― | 7.65% | -19.13% | |
52 Neutral | AU$199.54M | -7.55 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$89.38M | -9.01 | -49.72% | ― | ― | 10.78% | |
45 Neutral | AU$8.84M | ― | -469.35% | ― | ― | 46.28% | |
41 Neutral | AU$28.71M | -36.00 | -30.33% | ― | ― | ― |
Radiopharm Theranostics Limited Corporate Events
Radiopharm Theranostics Limited has notified the ASX that 400,000 options with an exercise price of A$0.60, expiring on 22 December 2025 and trading under the code RADAH, have lapsed unexercised. The expiry slightly reduces the company’s pool of potential dilutive securities but does not involve any new capital raising or share issuance, suggesting a minor housekeeping adjustment to its capital structure rather than a shift in strategy or operations for existing shareholders.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics has disclosed a change in the interests of director Paul Hopper, who was issued 18,142,000 unlisted options as approved by shareholders at the company’s Annual General Meeting on 20 November 2025. Following this non-cash issuance, Hopper’s direct holdings increased to 53,900,000 shares and 53,642,000 options, with his total direct and indirect option interests rising to 62,659,518, signalling continued alignment of the director’s incentives with shareholder interests and the company’s long-term strategic objectives.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics has disclosed a change in director Ian Turner’s interests in the company’s securities, following shareholder approval at the 20 November 2025 Annual General Meeting. Turner has been issued 6,814,000 additional unlisted options on a non-cash basis pursuant to a shareholder-approved resolution, increasing his total holding to 25,802,350 options (24,981,928 held directly and 820,422 indirectly), while his shareholding remains unchanged at 9,255,292 shares. The issuance reflects ongoing equity-based remuneration and further aligns the director’s incentives with shareholder interests, but does not involve any on-market transactions or changes to contractual interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has notified the market of the issue of 99,294,000 unquoted options under its employee incentive scheme, which are not intended to be quoted on the ASX and have various expiry dates and exercise prices. The issuance of these unquoted equity securities is designed to support the company’s remuneration and retention strategy by aligning employee incentives with shareholder interests, potentially leading to future dilution if the options are exercised, but also signaling a focus on long-term value creation and staff engagement.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the proposed issuance of 39,644,767 fully paid ordinary shares through a placement expected to occur on December 31, 2027. This move demonstrates the company’s commitment to further strengthening its capital base, potentially facilitating expansion, innovation in radiopharmaceutical development, and improved positioning within the industry as it continues to pursue technological advancement in cancer treatment and diagnostics.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the establishment of an At-the-Market (ATM) equity facility in the U.S., enabling the sale of American Depositary Shares (ADSs) to raise capital for product development and corporate needs. The ATM facility, which permits flexible, incremental fundraising based on prevailing market conditions, is a strategic move aiming to leverage U.S. capital markets, potentially raising up to $22.4 million initially with a wider $50 million ceiling over three years, enhancing the company’s financial flexibility in line with market trends.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited recently announced an inadvertent non-compliance with ASX Listing Rule 7.1 due to an oversights regarding the inclusion of milestone shares in its capacity calculation. This led to the company exceeding its placement capacity in October 2025, impacting the validity of certain placement shares for ratification. In response, the company intends to bolster its governance measures, increase awareness among officers, and engage external advisors to ensure full compliance and maintain best practices moving forward.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics announced that their Phase 2b trial of RAD 101 in brain metastases achieved its primary endpoint, with 92% of patients showing concordance with MRI imaging. This interim data bolsters confidence in the trial’s success and supports the potential initiation of a pivotal study by the end of 2026. The U.S. market opportunity for RAD 101 is estimated at over $500 million annually, positioning it as a top imaging agent. The trial has reached 50% patient enrollment and has received FDA Fast Track Designation, highlighting its significance in differentiating recurrent disease from treatment effects in brain metastases.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced that Paul Hopper has ceased to be a substantial holder in the company as of December 9, 2025. This change was due to a dilution from a placement, which affects the voting securities of the company. The announcement may impact the company’s shareholder structure and could influence its market dynamics.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has issued 750,960,477 ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with relevant provisions of the Corporations Act and confirms there is no excluded information required to be disclosed, indicating a strategic move to strengthen its financial position and potentially expand its market presence.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the application for quotation of new securities on the Australian Securities Exchange (ASX). The company plans to quote 750,960,477 ordinary fully paid shares and 1,166,666,667 options expiring in 2027, which could potentially strengthen its financial position and support its strategic growth initiatives in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company plans to issue 12,599,991 options expiring on October 31, 2027, at an exercise price of $0.039. This move is part of a securities purchase plan, which could potentially strengthen the company’s financial position and support its ongoing projects in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has released a holdings report indicating that a significant portion of its shares, 99.89%, is held by large stakeholders, with CITICORP NOMINEES PTY LIMITED being the largest shareholder at 36.96%. This concentration of ownership suggests a strong backing by major investors, potentially impacting the company’s strategic decisions and market influence.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced that all resolutions considered at their recent General Meeting were successfully passed by poll. These resolutions included the ratification of prior share placements and approvals for issuing additional shares and options, which are expected to support the company’s financial strategies and enhance its market position.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has successfully completed its share purchase plan (SPP), raising A$0.4 million, which contributes to a total of A$35.4 million raised alongside a placement announced earlier. The SPP offered new shares at A$0.03 each, and a total of 12,599,991 ordinary shares are scheduled to be issued. The issuance of SPP Attaching Options, with an exercise price of A$0.039 and expiring in October 2027, is also planned, reflecting the company’s strategic efforts to strengthen its financial position and support its operations.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Radiopharm Theranostics Ltd, a company involved in the development of radiopharmaceutical products. The change in substantial holding is due to transactions involving the rehypothecation of client securities and the purchase and sale of securities by J.P. Morgan Securities Australia Limited and J.P. Morgan Securities LLC. This development may impact the company’s shareholder structure and could influence its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced the cessation of 5,700,006 restricted options, which expired on November 25, 2025, without being exercised or converted. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth prospects.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced the cessation of Phillip Hains as a director, effective November 20, 2025. This change in directorship involves the transfer of his interests in securities, which include 9,900,002 unlisted options and 15,956,632 fully paid ordinary shares, along with 6,933,560 unlisted options held by a director-related entity. The announcement marks a significant shift in the company’s board composition, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced the cessation of Leila Alland as a director, effective November 20, 2025. This change in the board of directors may influence the company’s strategic direction and stakeholder relations, as the company continues to focus on its core mission in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced that all resolutions at their Annual General Meeting were passed by poll, with significant support for key resolutions. The meeting confirmed the re-appointment of Mr. Bruce Goodwin as a Non-Executive Director, indicating stability in the company’s governance. The approval of various resolutions, including the issuance of equity securities and incentive options, suggests strategic moves to strengthen the company’s operational capabilities and align management incentives with shareholder interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has released a presentation for its Annual General Meeting, highlighting key considerations for investors. The presentation emphasizes that it does not constitute personal investment advice and outlines the potential risks and uncertainties associated with the company’s clinical trials and regulatory approvals. Stakeholders are advised to seek professional investment advice and to be aware of the legal restrictions on the distribution of the presentation, particularly concerning securities laws in the United States.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the appointment of Bruce Goodwin as a director, effective from November 19, 2025. The initial director’s interest notice indicates that Bruce Goodwin currently holds no securities or interests in the company, which may suggest a neutral impact on the company’s immediate financial operations or market perception.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics has appointed Bruce Goodwin as a Non-Executive Director, bringing over four decades of experience in the life sciences sector, including a significant tenure at Janssen Pharmaceutical Companies of Johnson & Johnson. Goodwin’s strategic acumen and global perspective are expected to enhance Radiopharm’s efforts to advance its pipeline and strengthen its global profile, while the company also announces the retirement of two board members, Phillip Hains and Dr. Leila Alland, with Hains continuing in executive roles.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has received approval from the Bellberry Human Research Ethics Committee in Australia to initiate a Phase 1 clinical trial for its radiotherapeutic, RAD 402, targeting advanced prostate cancer. This trial marks a significant milestone as it is the first company-sponsored therapeutic trial using the radionuclide 161 Tb. The approval underscores the potential of RAD 402, which has shown promising preclinical results in targeting tumors with limited bone and marrow uptake, offering a novel mechanism for treating prostate cancer.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced that it has reached 50% patient enrollment in its Phase 2b clinical trial for RAD 101 imaging in brain metastases. The early data from the trial shows significant tumor uptake and confirms metabolic activity in brain metastases, which could lead to a global Phase 3 trial if results are confirmed. This milestone strengthens the company’s confidence in completing enrollment and sharing top-line results in the first half of 2026, potentially enhancing its position in the oncology radiopharmaceuticals market.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced the completion of enrollment for the second cohort of its Phase 1 dose escalation trial of 177Lu-RAD 204, targeting PD-L1 positive advanced cancers. The trial’s progression to the third cohort, with an increased dose, marks a significant milestone, potentially improving clinical outcomes for patients with limited treatment options.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced that Point72 Asset Management, L.P. has ceased to hold a long equity derivative position of 5% or more in the company’s ordinary shares as of October 27, 2025. This change in equity position, disclosed under the Australian Takeovers Panel Guidance Note 20, indicates a reduction in Point72’s investment in Radiopharm, potentially impacting the company’s shareholder structure and market perception.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics announced its participation in the Deutsche Bank ADR Virtual Investor Conference, where CEO Riccardo Canevari will present the company’s developments. Recent highlights include raising approximately A$35 million in capital and promising preliminary data from several clinical trials, including RAD 101, RAD 202, RAD 204, and RAD 301, indicating strong progress in their oncology radiopharmaceuticals pipeline.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced a change in the director’s interest as Riccardo Canevari acquired an additional 1,500,000 shares indirectly through an on-market trade, increasing his total indirect holdings to 2,650,000 shares. This acquisition reflects a strategic move by the director, potentially signaling confidence in the company’s future prospects and impacting shareholder perceptions positively.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a change in the substantial holding of Paul Hopper, a significant shareholder. The change, effective from October 24, 2025, reflects a decrease in his voting power from 6.9% to 5.3%, following a dilution through placement. This adjustment in shareholding may impact the company’s governance dynamics and shareholder influence.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has received IND approval from the FDA to begin a Phase I clinical study targeting B7H3 with Betabart, and has appointed Dr. Oliver Sartor to its Scientific Advisory Board. The company also announced positive updates across four clinical programs, with significant milestones expected in 2026, and secured a A$35 million institutional placement to support ongoing initiatives. The RAD 101 Phase 2b imaging study showed promising results in targeting brain metastases, while the RAD 202 Phase 1 ‘HEAT’ trial demonstrated higher-than-expected tumor uptake, supporting its potential as a novel HER2-directed radiotherapeutic.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced its upcoming Annual General Meeting, scheduled for November 20, 2025, which will be held both in-person in Victoria and virtually via the Automic Investor Portal. This hybrid meeting format aims to accommodate all shareholders, allowing them to participate, vote, and ask questions about the company’s operations and business matters, thereby enhancing shareholder engagement and transparency.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a target market determination for attaching options related to a share offer under a prospectus dated October 20, 2025. The offer is aimed at investors seeking exposure to the radiopharmaceutical sector, with potential for capital growth and inclusion in a diversified portfolio. The attaching options are designed for those with a medium to long-term investment timeframe and the financial capacity to handle the speculative nature of the investment. The offer is managed by Bell Potter Securities Limited and is available to eligible shareholders in Australia and New Zealand.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a Share Purchase Plan (SPP) offering eligible shareholders the opportunity to subscribe for up to $30,000 of new shares at an issue price of $0.03 per share. This initiative, which includes a free attaching option for every new share issued, aims to raise $5 million, potentially strengthening the company’s financial position and enabling further development of its radiopharmaceutical products.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a clinical update and capital raising initiative. The announcement highlights the company’s ongoing efforts to advance its clinical trials and secure necessary funding to support its operations. This move is expected to bolster the company’s financial position and enhance its capability to bring innovative radiopharmaceutical solutions to the market, potentially impacting its industry standing and stakeholder interests.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced positive clinical updates across four of its programs, highlighting significant advancements in its pipeline. The company reported promising preliminary data from its Phase 2b imaging clinical trial of RAD 101, Phase 1 trials of RAD 202 and RAD 204, and a Phase 1 study of RAD 301, all showing potential in targeting various cancer types. These developments underscore the company’s strategic execution and commitment to advancing its clinical programs, with expectations for further data readouts and trial progressions in the near term.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a proposed issue of securities, including options expiring in 2027 and ordinary fully paid shares, scheduled for issuance on December 10, 2025. This move is part of the company’s strategy to raise capital, potentially impacting its market position by enhancing its financial resources for ongoing and future projects, thereby influencing stakeholders’ interests and the company’s operational capabilities.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has announced a proposed issue of securities under a securities purchase plan, offering a total of 166,666,667 new securities. This move is part of the company’s strategy to raise capital, potentially enhancing its financial position and supporting its ongoing projects in the radiopharmaceutical sector. The offer is set to close on November 28, 2025, with the issue date scheduled for December 5, 2025.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited announced a proposed issue of 415,706,190 ordinary fully paid securities, with the issue date set for October 24, 2025. This strategic move is likely aimed at raising capital to support the company’s ongoing projects and enhance its market position in the theranostics sector, potentially impacting stakeholders by increasing the company’s financial resources and operational capabilities.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has successfully completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan. The funds raised will be used to support drug manufacturing, clinical trials, and working capital, extending the company’s funding runway into 2027. The placement was strongly supported by both new and existing investors, including Lantheus Holdings, which increased its shareholding to 14.5%. This financial boost is expected to advance Radiopharm’s six clinical programs and strengthen its position in the radiopharmaceutical industry.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
Radiopharm Theranostics Limited has requested a trading halt on its securities pending an announcement related to a capital raising effort. The halt is expected to last until the announcement is made or until the market opens on October 20, 2025. This move indicates a significant financial maneuver that could impact the company’s operations and market positioning.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.